A new targeted antibody treatment for ovarian cancer
Official title: A novel targeted antibody therapeutic to treat ovarian cancer
Funded at Trio Pharmaceuticals INC. · NIH-10820095 · Data updated 2026-11-12
This study is testing a new treatment for ovarian cancer that helps your immune system fight the disease better by targeting harmful cells in the tumor, and it's designed for women who haven't had success with regular chemotherapy.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Trio Pharmaceuticals INC. NIH-funded |
| Lab location | 1 site (Murrieta, United States) |
| Project start | June 1, 2024 |
| Project end | May 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $399,478 |
| NIH project number | 1R43CA287501-01 |
| Project ID | NIH-10820095 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are women diagnosed with ovarian cancer who have not responded adequately to existing chemotherapy treatments.
✕Less likely to help
Patients with early-stage ovarian cancer or those who have not yet undergone chemotherapy may not benefit from this research.
What this research studies
This research focuses on developing a targeted antibody therapeutic specifically designed to treat ovarian cancer, which is a leading cause of cancer deaths among women. The approach aims to enhance the immune system's ability to fight tumors by selectively targeting and eliminating immunosuppressive cells in the tumor microenvironment, while also attacking cancer cells. By addressing the limitations of current immuno-oncology drugs, this research seeks to provide a more effective treatment option for patients who have not responded well to traditional chemotherapy. The study will involve clinical trials to evaluate the safety and efficacy of this novel therapeutic.
Why it matters
Potential benefit: If successful, this research could lead to a more effective treatment for ovarian cancer, potentially improving survival rates and quality of life for patients.
How similar studies have gone: While immuno-oncology approaches have shown promise in other cancers, this specific targeted antibody therapeutic represents a novel approach that has not yet been tested in clinical settings for ovarian cancer.
Where this research is happening
-
Trio Pharmaceuticals INC.
Murrieta, United States Active
Researchers
- Principal investigator: Laus, Reiner — Trio Pharmaceuticals INC.
- Study coordinator: Laus, Reiner
Related research
Other NIH-funded projects on the same topics.
-
Understanding the experience of ovarian cancer after diagnosis to improve survivorship
This NIH grant funds a mixed-methods study to better understand physical and emotional challenges faced by ovarian cancer survivors and how supportive care can help them live better after diagnosis.
-
Targeting quiescent ovarian cancer cells to overcome chemotherapy resistance
A study focusing on why some ovarian cancer cells pause dividing and resist chemotherapy, with the goal of finding new treatment targets for relapsed disease.
-
Photodynamic lipids to boost chemotherapy for metastatic ovarian cancer
A patient-friendly approach tests a light-activated method to make ovarian cancer metastases more sensitive to chemotherapy.
-
Integrated framework to validate and quantify proteoforms in patient-derived ovarian cancer cells
A collaboration will combine advanced top-down proteomics with a new computational method to precisely identify and measure intact proteoforms in tiny samples from ovarian cancer cells.
-
Overcoming platinum resistance in ovarian cancer: finding biomarkers and new targets
Researchers are looking for new biomarkers and targets to help prevent or overcome platinum resistance in high‑risk ovarian cancer so patients have better chances at long-term control.
-
Alternative NF-kB activation after chemotherapy in ovarian cancer
This grant studies how ovarian cancer might come back after chemotherapy by looking at specific signaling pathways in cancer cells and the tumor environment.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.